• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Dr Reddy’s Laboratories launches Redyx (remdesivir) in India

expresspharmaSeptember 18, 2020

Tag: Dr Reddy , Redyx , India , Remdesivir

Dr Reddy’s Laboratories announced the launch of Remdesivir, under a brand name Redyx in India. The launch is part of the licensing agreement with Gilead Sciences that grants Dr Reddy’s the right to register, manufacture and sell Remdesivir, a potential treatment for COVID-19, in 127 countries including India.

Dr Reddy’s Redyx is available in the strength of 100 mg vial.

M V Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories, said, “The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”

Previous:Scientists at University of Sheffield discover new drug to treat pancreatic cancer

Next:Neovascularization inhibitor sales will near $7 bn in diabetic retinopathy market in 2029: GlobalData

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Dr Reddy’s Laboratories launches Redyx (remdesivir) in India | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Remdesivir amino ester compound

Remdesivir amino ester compound
Remdesivir Intermediate

Remdesivir Intermediate
Remdesivir

Remdesivir
Remdesivir

Remdesivir
Remdesivir

Remdesivir
Remdesivir Chloro compound

Remdesivir Chloro compound
Remdesivir

Remdesivir
Indian Trum etflower Seed Extract

Indian Trum etflower Seed Extract

99% up by HPLC USP GMP DMF Remdesivir 1809249-37-3

99% up by HPLC USP GMP DMF Remdesivir 1809249-37-3
Remdesivir

Remdesivir

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service